S
Salomon M. Stemmer
Researcher at Rabin Medical Center
Publications - 215
Citations - 12740
Salomon M. Stemmer is an academic researcher from Rabin Medical Center. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 43, co-authored 189 publications receiving 9651 citations. Previous affiliations of Salomon M. Stemmer include University of New South Wales & Tel Aviv University.
Papers
More filters
The Reprogramming of Tumor Stroma by HSF1 Is a Potent Enabler of Malignancy
Ruth Scherz-Shouval,Sandro Santagata,Marc L. Mendillo,Lynette M. Sholl,Irit Ben-Aharon,Andrew H. Beck,Dora Dias-Santagata,Salomon M. Stemmer,Luke Whitesell,Martina Koeva,Susan Lindquist +10 more
TL;DR: In this article, the authors report that the transcriptional regulator heat shock factor 1 (HSF1) is frequently activated in cancer-associated fibroblasts (CAFs), where it is a potent enabler of malignancy.
Journal ArticleDOI
BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial
Bruno Bockorny,Bruno Bockorny,Valerya Semenisty,Teresa Macarulla,Erkut Borazanci,Brian M. Wolpin,Salomon M. Stemmer,Salomon M. Stemmer,Talia Golan,Talia Golan,Ravit Geva,Ravit Geva,Mitesh J. Borad,Katrina S. Pedersen,Joon Oh Park,Robert A. Ramirez,David Gutierrez Abad,Jaime Feliu,Andrés Muñoz,Mariano Ponz-Sarvise,Amnon Peled,Tzipora M. Lustig,Osnat Bohana-Kashtan,Stephen M. Shaw,Ella Sorani,Marya F. Chaney,Shaul Kadosh,Abi Vainstein Haras,Daniel D. Von Hoff,Manuel Hidalgo,Manuel Hidalgo +30 more
TL;DR: Results from the phase IIa COMBAT trial combining CXCR4 and PD-1 inhibition in patients with metastatic cancer show encouraging clinical responses in association with enhanced antitumor immune activation.
Journal ArticleDOI
Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy
Susan M. Domchek,Carol Aghajanian,Ronnie Shapira-Frommer,Rita K. Schmutzler,M. William Audeh,Michael Friedlander,Judith Balmaña,Gillian Mitchell,Gillian Mitchell,Georgeta Fried,Salomon M. Stemmer,Ayala Hubert,Ora Rosengarten,Niklas Loman,Jane Robertson,Helen Mann,Bella Kaufman +16 more
TL;DR: Following ≥3 prior lines of chemotherapy, olaparib 400mg bid (capsule form) monotherapy demonstrated notable antitumor activity in patients with gBRCA1/2m advanced ovarian cancer and no new safety signals were identified.
Journal ArticleDOI
Evaluation of Seropositivity Following BNT162b2 Messenger RNA Vaccination for SARS-CoV-2 in Patients Undergoing Treatment for Cancer.
Amir Massarweh,Noa Eliakim-Raz,Noa Eliakim-Raz,Amos Stemmer,Adva Levy-Barda,Shlomit Yust-Katz,Shlomit Yust-Katz,Alona Zer,Alona Zer,Alexandra Benouaich-Amiel,Haim Ben-Zvi,Haim Ben-Zvi,Neta Moskovits,Baruch Brenner,Baruch Brenner,Jihad Bishara,Jihad Bishara,Dafna Yahav,Dafna Yahav,Boaz Tadmor,Tal Zaks,Salomon M. Stemmer,Salomon M. Stemmer +22 more
TL;DR: In this paper, the authors evaluated rates of antispike (anti-S) antibody response to a BNT162b2 vaccine in patients with cancer who are undergoing systemic treatment vs healthy controls.
Journal ArticleDOI
Dose-Dense Chemotherapy in Nonmetastatic Breast Cancer: A Systematic Review and Meta-analysis of Randomized Controlled Trials
Luisa Bonilla,Irit Ben-Aharon,Liat Vidal,Anat Gafter-Gvili,Leonard Leibovici,Salomon M. Stemmer +5 more
TL;DR: Dose-dense chemotherapy results in better overall and disease-free survival, particularly in women with hormone receptor–negative breast cancer, however, additional data from randomized controlled trials are needed before dose- dense chemotherapy can be considered as the standard of care.